TRLV Company Profile and Key Details

Average 10-day trading volume of 1.86 million shares is slightly above the 3-month average of 1.27 million, indicating heightened recent market interest.

Trulieve Cannabis Corp. has 169.98 million shares outstanding. The public float is 167.89 million shares, elevated short interest at 0.80% of float. This equals 1.32 million shares. The short ratio is 1.44 days. Institutional investors hold 21.7% of the float. Insiders own 1.34%. Over the past six months, insider transactions show net selling. They sold 1.70 million shares across 7 transactions.

Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 0 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $15.00 to $15.00. The high target offers 29.31% upside. The low target suggests 29.31% downside. The mean target is $15.00. This offers 29.31% upside. Trulieve Cannabis Corp. earnings surprise history is a mixed track record. The quarter that ended August 07, 2026, missed forecasts by -2544.11%. The prior quarter beat by -2544.11%. Over the last six quarters, Apple has recorded several small beats. These include 196.22% in February 26, 2026.

Trulieve Cannabis Corp. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $10.68. This means the shares are trading above this model’s fair value.

Trulieve Cannabis Corp. (NYSE:TRLV) closed at $11.60 USD, losing -$0.02 (-0.17%) from the previous close of $11.62. The stock is currently mid-range between its 52-week high and low $4.62 and $13.28. With a market capitalization of about $1.97 billion, Trulieve Cannabis Corp. is classified as a small-cap and shows higher-than-market volatility (beta ~1.76). Key stats such as the average daily volume over the past year has been around 1.30 million shares, in line with its 52-week average. Headquartered in Tallahassee, FL, Trulieve Cannabis Corp. operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Kimberly A. Rivers, the company employs approximately 5,000 people and listed since September 25, 2018. Trulieve Cannabis Corp. engages in the cultivation, processing, manufacturing, and retail distribution of medical and adult-use cannabis products.

Valuation shows Trulieve Cannabis Corp. trading at a premium to the broader market with a P/E of -4.68. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $15.00, suggesting 29.31% upside. Our AI forecast model points to short-term strength (6.55% over two weeks), a medium-term rise (92.67% over three months), and a longer-term loss (-25.95% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Trulieve Cannabis Corp. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 6.55%, with price expected at $12.36 by September 29, 2026, within a range of $11.90 to $12.79 3-Month Outlook: Projected rise of 92.67%, reaching $22.35 by December 14, 2026, with a range of $22.28 to $22.40. 1-Year Outlook: Projected loss of -25.95%, with price at $8.59 by September 15, 2027, within a range of $8.51 to $8.66.

Trulieve Cannabis Corp. trades at a P/E ratio of -4.68, slightly below the S&P 500 average, with a price-to-sales ratio of 1.71 and a price-to-book ratio of 2.88 suggesting the stock is closer to book value. The P/FCF stands at 10.43, also above market averages.